{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:41:32Z","timestamp":1791499292847,"version":"4.3.4"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,1,24]],"date-time":"2022-01-24T00:00:00Z","timestamp":1642982400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,24]],"date-time":"2022-01-24T00:00:00Z","timestamp":1642982400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100012551","name":"Applied Basic Research Program of Sichuan Province","doi-asserted-by":"publisher","award":["2021YJ0450"],"award-info":[{"award-number":["2021YJ0450"]}],"id":[{"id":"10.13039\/100012551","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010822","name":"Chengdu Science and Technology Bureau","doi-asserted-by":"crossref","award":["2019-GH02-00036-HZ"],"award-info":[{"award-number":["2019-GH02-00036-HZ"]}],"id":[{"id":"10.13039\/501100010822","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100013365","name":"West China Hospital, Sichuan University","doi-asserted-by":"publisher","award":["2019HXBH017"],"award-info":[{"award-number":["2019HXBH017"]}],"id":[{"id":"10.13039\/501100013365","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1007\/s00280-021-04386-z","type":"journal-article","created":{"date-parts":[[2022,1,24]],"date-time":"2022-01-24T00:05:01Z","timestamp":1642982701000},"page":"331-346","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Repurposed antipsychotic chlorpromazine inhibits colorectal cancer and pulmonary metastasis by inducing G2\/M cell cycle arrest, apoptosis, and autophagy"],"prefix":"10.1007","volume":"89","author":[{"given":"Fuyan","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huizhi","family":"Xi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengya","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiqian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongbo","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengling","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongbao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiwen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7939-9995","authenticated-orcid":false,"given":"Yong","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,24]]},"reference":[{"issue":"3","key":"4386_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"issue":"9","key":"4386_CR2","doi-asserted-by":"publisher","DOI":"10.1002\/bjs.11789","volume":"107","author":"M Baum","year":"2020","unstructured":"Baum M, Fallowfield L, Farewell V, Macbeth F, Treasure T (2020) NICE guidelines: management of colorectal cancer metastases. Br J Surg 107(9):e357. https:\/\/doi.org\/10.1002\/bjs.11789","journal-title":"Br J Surg"},{"key":"4386_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2020.103811","volume":"99","author":"A Ayati","year":"2020","unstructured":"Ayati A, Moghimi S, Salarinejad S, Safavi M, Pouramiri B, Foroumadi A (2020) A review on progression of epidermal growth factor receptor (EGFR) inhibitors as an efficient approach in cancer targeted therapy. Bioorg Chem 99:103811. https:\/\/doi.org\/10.1016\/j.bioorg.2020.103811","journal-title":"Bioorg Chem"},{"issue":"1","key":"4386_CR4","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/nrd.2018.168","volume":"18","author":"S Pushpakom","year":"2019","unstructured":"Pushpakom S, Iorio F, Eyers PA, Escott KJ, Hopper S, Wells A, Doig A, Guilliams T, Latimer J, McNamee C, Norris A, Sanseau P, Cavalla D, Pirmohamed M (2019) Drug repurposing: progress, challenges and recommendations. Nat Rev Drug Discov 18(1):41\u201358. https:\/\/doi.org\/10.1038\/nrd.2018.168","journal-title":"Nat Rev Drug Discov"},{"issue":"9","key":"4386_CR5","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.tips.2013.06.005","volume":"34","author":"SC Gupta","year":"2013","unstructured":"Gupta SC, Sung B, Prasad S, Webb LJ, Aggarwal BB (2013) Cancer drug discovery by repurposing: teaching new tricks to old dogs. Trends Pharmacol Sci 34(9):508\u2013517","journal-title":"Trends Pharmacol Sci"},{"key":"4386_CR6","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.canlet.2017.01.042","volume":"393","author":"SJ Dilly","year":"2017","unstructured":"Dilly SJ, Clark AJ, Marsh A, Mitchell DA, Cain R, Fishwick CWG, Taylor PC (2017) A chemical genomics approach to drug reprofiling in oncology: antipsychotic drug risperidone as a potential adenocarcinoma treatment. Cancer Lett 393:16\u201321","journal-title":"Cancer Lett"},{"issue":"2\u20133","key":"4386_CR7","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.schres.2011.02.018","volume":"129","author":"FH Chou","year":"2011","unstructured":"Chou FH, Tsai KY, Su CY, Lee CC (2011) The incidence and relative risk factors for developing cancer among patients with schizophrenia: a nine-year follow-up study. Schizophr Res 129(2\u20133):97\u2013103","journal-title":"Schizophr Res"},{"issue":"7","key":"4386_CR8","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1038\/sj.bjc.6603259","volume":"95","author":"S Dalton","year":"2006","unstructured":"Dalton S, Johansen C, Ah NM, Sorensen H, Mclaughlin J, Mortensen P, Friis S (2006) Cancer risk among users of neuroleptic medication: a population-based cohort study. Brit J Cancer 95(7):934\u2013939","journal-title":"Brit J Cancer"},{"issue":"3","key":"4386_CR9","first-page":"459","volume":"9","author":"F Xu","year":"2019","unstructured":"Xu F, Xia Y, Feng Z, Lin W, Xue Q, Jiang J, Yu X, Peng C, Luo M, Yang Y, Wei Y, Yu L (2019) Repositioning antipsychotic fluphenazine hydrochloride for treating triple negative breast cancer with brain metastases and lung metastases. Am J Cancer Res 9(3):459\u2013478","journal-title":"Am J Cancer Res"},{"key":"4386_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2020.105295","volume":"163","author":"Y Xia","year":"2021","unstructured":"Xia Y, Xu F, Xiong M, Yang H, Lin W, Xie Y, Xi H, Xue Q, Ye T, Yu L (2021) Repurposing of antipsychotic trifluoperazine for treating brain metastasis, lung metastasis and bone metastasis of melanoma by disrupting autophagy flux. Pharmacol Res 163:105295. https:\/\/doi.org\/10.1016\/j.phrs.2020.105295","journal-title":"Pharmacol Res"},{"issue":"23","key":"4386_CR11","doi-asserted-by":"publisher","first-page":"37568","DOI":"10.18632\/oncotarget.17247","volume":"8","author":"CR Oliva","year":"2017","unstructured":"Oliva CR, Zhang W, Langford C, Suto MJ, Griguer CE (2017) Repositioning chlorpromazine for treating chemoresistant glioma through the inhibition of cytochrome c oxidase bearing the COX4-1 regulatory subunit. Oncotarget 8(23):37568\u201337583","journal-title":"Oncotarget"},{"issue":"9","key":"4386_CR12","doi-asserted-by":"publisher","first-page":"2080","DOI":"10.1093\/carcin\/bgt169","volume":"34","author":"SY Shin","year":"2013","unstructured":"Shin SY, Lee KS, Choi YK, Lim HJ, Lee HG, Lim Y, Lee YH (2013) The antipsychotic agent chlorpromazine induces autophagic cell death by inhibiting the Akt\/mTOR pathway in human U-87MG glioma cells. Carcinogenesis 34(9):2080\u20132089","journal-title":"Carcinogenesis"},{"key":"4386_CR13","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.cbi.2019.01.033","volume":"302","author":"CE Yang","year":"2019","unstructured":"Yang CE, Lee WY, Cheng HW, Chung CH, Mi FL, Lin CW (2019) The antipsychotic chlorpromazine suppresses YAP signaling, stemness properties, and drug resistance in breast cancer cells. Chem Biol Interact 302:28\u201335. https:\/\/doi.org\/10.1016\/j.cbi.2019.01.033","journal-title":"Chem Biol Interact"},{"issue":"29","key":"4386_CR14","doi-asserted-by":"publisher","first-page":"27580","DOI":"10.18632\/oncotarget.4768","volume":"6","author":"WY Lee","year":"2015","unstructured":"Lee WY, Lee WT, Cheng CH, Chen KC, Chou CM, Chung CH, Sun MS, Cheng HW, Ho MN, Lin CW (2015) Repositioning antipsychotic chlorpromazine for treating colorectal cancer by inhibiting sirtuin 1. Oncotarget 6(29):27580\u201327595. https:\/\/doi.org\/10.18632\/oncotarget.4768","journal-title":"Oncotarget"},{"issue":"1029","key":"4386_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fphar.2019.01029","volume":"10","author":"Y Xia","year":"2019","unstructured":"Xia Y, Jia C, Xue Q, Jiang J, Xie Y, Wang R, Ran Z, Xu F, Zhang Y, Ye T (2019) Antipsychotic drug trifluoperazine suppresses colorectal cancer by inducing G0\/G1 arrest and apoptosis. Front Pharmacol 10(1029):1\u201314. https:\/\/doi.org\/10.3389\/fphar.2019.01029","journal-title":"Front Pharmacol"},{"key":"4386_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.110274","volume":"128","author":"Q Sun","year":"2020","unstructured":"Sun Q, Yu X, Peng C, Liu N, Chen W, Xu H, Wei H, Fang K, Dong Z, Fu C, Xu Y, Lu W (2020) Activation of SREBP-1c alters lipogenesis and promotes tumor growth and metastasis in gastric cancer. Biomed Pharmacother 128:110274. https:\/\/doi.org\/10.1016\/j.biopha.2020.110274","journal-title":"Biomed Pharmacother"},{"key":"4386_CR17","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/s41420-018-0032-y","volume":"4","author":"WJ Lu","year":"2018","unstructured":"Lu WJ, Peng W, Sun QQ, Li YH, Chen B, Yu LT, Xu YZ, Wang SY, Zhao YL (2018) #2714, a novel active inhibitor with potent G2\/M phase arrest and antitumor efficacy in preclinical models. Cell death discovery 4:24. https:\/\/doi.org\/10.1038\/s41420-018-0032-y","journal-title":"Cell death discovery"},{"issue":"10","key":"4386_CR18","doi-asserted-by":"publisher","first-page":"13474","DOI":"10.1096\/fj.202000950R","volume":"34","author":"N Liu","year":"2020","unstructured":"Liu N, Sun Q, Xu H, Yu X, Chen W, Wei H, Jiang J, Xu Y, Lu W (2020) Hyperuricemia induces lipid disturbances mediated by LPCAT3 upregulation in the liver. FASEB J: Off Publ Fed Am Soc Exp Biol 34(10):13474\u201313493. https:\/\/doi.org\/10.1096\/fj.202000950R","journal-title":"FASEB J: Off Publ Fed Am Soc Exp Biol"},{"issue":"1","key":"4386_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/15548627.2020.1797280","volume":"17","author":"DJ Klionsky","year":"2021","unstructured":"Klionsky DJ, Abdel-Aziz AK, Abdelfatah S, Abdellatif M, Abdoli A, Abel S, Abeliovich H, Abildgaard MH, Abudu YP et al (2021) Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)(1). Autophagy 17(1):1\u2013382. https:\/\/doi.org\/10.1080\/15548627.2020.1797280","journal-title":"Autophagy"},{"issue":"24","key":"4386_CR20","doi-asserted-by":"publisher","first-page":"7527","DOI":"10.1158\/1078-0432.ccr-19-0516","volume":"25","author":"L Yang","year":"2019","unstructured":"Yang L, Qiu Q, Tang M, Wang F, Yi Y, Yi D, Yang Z, Zhu Z, Zheng S, Yang J, Pei H, Zheng L, Chen Y, Gou L, Luo L, Deng X, Ye H, Hu Y, Niu T, Chen L (2019) Purinostat mesylate is a uniquely potent and selective inhibitor of HDACs for the treatment of BCR-ABL-induced B-cell acute lymphoblastic leukemia. Clin Cancer Res 25(24):7527\u20137539. https:\/\/doi.org\/10.1158\/1078-0432.ccr-19-0516","journal-title":"Clin Cancer Res"},{"issue":"19","key":"4386_CR21","doi-asserted-by":"publisher","first-page":"7099","DOI":"10.1158\/0008-5472.can-04-1443","volume":"64","author":"SM Wilhelm","year":"2004","unstructured":"Wilhelm SM, Carter C, Tang LY, Wilkie D, McNabola A, Rong H, Chen C, Zhang XM, Vincent P, McHugh M, Cao YC, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE, Bollag G, Trail PA (2004) BAY 43\u20139006 exhibits broad spectrum oral antitumor activity and targets the RAF\/MEK\/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64(19):7099\u20137109. https:\/\/doi.org\/10.1158\/0008-5472.can-04-1443","journal-title":"Cancer Res"},{"key":"4386_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2019.113676","volume":"170","author":"M Bonelli","year":"2019","unstructured":"Bonelli M, La Monica S, Fumarola C, Alfieri R (2019) Multiple effects of CDK4\/6 inhibition in cancer: from cell cycle arrest to immunomodulation. Biochem Pharmacol 170:113676. https:\/\/doi.org\/10.1016\/j.bcp.2019.113676","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"4386_CR23","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.cell.2012.03.003","volume":"149","author":"V Chi","year":"2012","unstructured":"Chi V, Dang (2012) MYC on the path to cancer. Cell 149(1):22\u201335","journal-title":"Cell"},{"key":"4386_CR24","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/s41422-019-0164-5","volume":"29","author":"D Tang","year":"2019","unstructured":"Tang D, Kang R, Berghe TV, Vandenabeele P, Kroemer G (2019) The molecular machinery of regulated cell death. Cell Res 29:347\u2013364","journal-title":"Cell Res"},{"issue":"3","key":"4386_CR25","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1002\/ijc.31069","volume":"142","author":"S Rodic","year":"2018","unstructured":"Rodic S, Vincent MD (2018) Reactive oxygen species (ROS) are a key determinant of cancer\u2019s metabolic phenotype. Int J Cancer 142(3):440\u2013448. https:\/\/doi.org\/10.1002\/ijc.31069","journal-title":"Int J Cancer"},{"key":"4386_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2020.114403","volume":"184","author":"AJ Jhou","year":"2021","unstructured":"Jhou AJ, Chang HC, Hung CC, Lin HC, Lee YC, Liu WT, Han KF, Lai YW, Lin MY, Lee CH (2021) Chlorpromazine, an antipsychotic agent, induces G2\/M phase arrest and apoptosis via regulation of the PI3K\/AKT\/mTOR-mediated autophagy pathways in human oral cancer. Biochem Pharmacol 184:114403. https:\/\/doi.org\/10.1016\/j.bcp.2020.114403","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"4386_CR27","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1080\/15548627.2019.1598752","volume":"16","author":"J Jiang","year":"2020","unstructured":"Jiang J, Zhang L, Chen H, Lei Y, Zhang T, Wang Y, Jin P, Lan J, Zhou L, Huang Z, Li B, Liu Y, Gao W, Xie K, Zhou L, Nice EC, Peng Y, Cao Y, Wei Y, Wang K, Huang C (2020) Regorafenib induces lethal autophagy arrest by stabilizing PSAT1 in glioblastoma. Autophagy 16(1):106\u2013122. https:\/\/doi.org\/10.1080\/15548627.2019.1598752","journal-title":"Autophagy"},{"issue":"3","key":"4386_CR28","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1172\/jci123319","volume":"129","author":"RM Chabanon","year":"2019","unstructured":"Chabanon RM, Muirhead G, Krastev DB, Adam J, Morel D, Garrido M, Lamb A, Henon C, Dorvault N, Rouanne M, Marlow R, Bajrami I, Cardenosa ML, Konde A, Besse B, Ashworth A, Pettitt SJ, Haider S, Marabelle A, Tutt ANJ, Soria J-C, Lord CJ, Postel-Vinay S (2019) PARP inhibition enhances tumor cell-intrinsic immunity in ERCC1-deficient non-small cell lung cancer. J Clin Invest 129(3):1211\u20131228. https:\/\/doi.org\/10.1172\/jci123319","journal-title":"J Clin Invest"},{"issue":"16","key":"4386_CR29","doi-asserted-by":"publisher","first-page":"6558","DOI":"10.18632\/oncotarget.2289","volume":"5","author":"K Michiel","year":"2014","unstructured":"Michiel K, Paul G, Brok IC, Inna A, Hoogerbrugge PM, Adema GJ (2014) HDAC inhibitors and immunotherapy; a double edged sword? Oncotarget 5(16):6558\u20136572","journal-title":"Oncotarget"},{"key":"4386_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2020.612347","author":"NN Muric","year":"2020","unstructured":"Muric NN, Arsenijevic NN, Borovcanin MM (2020) Chlorpromazine as a potential antipsychotic choice in COVID-19 treatment. Front Psychiatry. https:\/\/doi.org\/10.3389\/fpsyt.2020.612347","journal-title":"Front Psychiatry"},{"issue":"2","key":"4386_CR31","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1097\/00005792-199003000-00003","volume":"69","author":"S Zucker","year":"1990","unstructured":"Zucker S, Zarrabi HM, Schubach WH, Varma A, Derman R, Lysik RM, Habicht G, Seitz PM (1990) Chlorpromazine-induced immunopathy: progressive increase in serum IgM. Medicine 69(2):92\u2013100","journal-title":"Medicine"},{"issue":"2","key":"4386_CR32","first-page":"217","volume":"79","author":"R Bertini","year":"1993","unstructured":"Bertini R, Garattini S, Delgado R, Ghezzi P (1993) Pharmacological activities of chlorpromazine involved in the inhibition of tumour necrosis factor production in vivo in mice. Immunology 79(2):217\u2013219","journal-title":"Immunology"},{"issue":"2","key":"4386_CR33","doi-asserted-by":"crossref","first-page":"861","DOI":"10.4049\/jimmunol.154.2.861","volume":"154","author":"R Tarazona","year":"1995","unstructured":"Tarazona R, Gonz\u00e1lez-Garc\u00eda A, Zamzami N, Marchetti P, Frechin N, Gonzalo JA, Ruiz-Gayo M, van Rooijen N, Mart\u00ednez C, Kroemer G (1995) Chlorpromazine amplifies macrophage-dependent IL-10 production in vivo. J Immunol 154(2):861\u2013870","journal-title":"J Immunol"},{"issue":"6","key":"4386_CR34","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1084\/jem.173.6.1305","volume":"173","author":"M Gadina","year":"1991","unstructured":"Gadina M, Bertini R, Mengozzi M, Zandalasini M, Mantovani A, Ghezzi P (1991) Protective effect of chlorpromazine on endotoxin toxicity and TNF production in glucocorticoid-sensitive and glucocorticoid-resistant models of endotoxic shock. J Exp Med 173(6):1305\u20131310. https:\/\/doi.org\/10.1084\/jem.173.6.1305","journal-title":"J Exp Med"},{"issue":"10","key":"4386_CR35","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1016\/j.jpsychires.2011.04.009","volume":"45","author":"H Himmerich","year":"2011","unstructured":"Himmerich H, Sch\u00f6nherr J, Fulda S, Sheldrick AJ, Bauer K, Sack U (2011) Impact of antipsychotics on cytokine production in-vitro. J Psychiatr Res 45(10):1358\u20131365. https:\/\/doi.org\/10.1016\/j.jpsychires.2011.04.009","journal-title":"J Psychiatr Res"},{"issue":"1","key":"4386_CR36","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.euroneuro.2004.04.002","volume":"15","author":"K Labuzek","year":"2005","unstructured":"Labuzek K, Kowalski J, Gabryel B, Herman ZS (2005) Chlorpromazine and loxapine reduce interleukin-1\u03b2 and interleukin-2 release by rat mixed glial and microglial cell cultures. Eur Neuropsychopharmacol 15(1):23\u201330. https:\/\/doi.org\/10.1016\/j.euroneuro.2004.04.002","journal-title":"Eur Neuropsychopharmacol"},{"issue":"4","key":"4386_CR37","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.clcc.2015.05.009","volume":"14","author":"M Michl","year":"2015","unstructured":"Michl M, Thurmaier J, Schubert-Fritschle G, Wiedemann M, Laubender RP, N\u00fcssler NC, Ruppert R, Kleeff J, Schepp W, Reuter C (2015) Brain metastasis in colorectal cancer patients: survival and analysis of prognostic factors. Clin Colorectal Cancer 14(4):281\u2013290","journal-title":"Clin Colorectal Cancer"},{"key":"4386_CR38","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.canlet.2018.04.039","volume":"428","author":"J Basso","year":"2018","unstructured":"Basso J, Miranda A, Sousa J, Pais A, Vitorino C (2018) Repurposing drugs for glioblastoma: from bench to bedside. Cancer Lett 428:173\u2013183","journal-title":"Cancer Lett"},{"key":"4386_CR39","doi-asserted-by":"publisher","first-page":"500","DOI":"10.3389\/fphys.2018.00500","volume":"9","author":"B Turanli","year":"2018","unstructured":"Turanli B, Gr\u00f8tli M, Boren J, Nielsen J, Uhlen M, Arga KY, Mardinoglu A (2018) Drug repositioning for effective prostate cancer treatment. Front Physiol 9:500","journal-title":"Front Physiol"},{"issue":"5","key":"4386_CR40","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):646\u2013674","journal-title":"Cell"},{"issue":"3","key":"4386_CR41","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1046\/j.1365-2184.2003.00266.x","volume":"36","author":"K Vermeulen","year":"2003","unstructured":"Vermeulen K, Van Bockstaele DR, Berneman ZN (2003) The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer. Cell Proliferat 36(3):131\u2013149","journal-title":"Cell Proliferat"},{"issue":"7015","key":"4386_CR42","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1038\/nature03097","volume":"432","author":"MB Kastan","year":"2004","unstructured":"Kastan MB, Jiri B (2004) Cell-cycle checkpoints and cancer. Nature 432(7015):316","journal-title":"Nature"},{"issue":"3","key":"4386_CR43","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1054\/bjoc.1999.0976","volume":"82","author":"C Badie","year":"2000","unstructured":"Badie C, Bourhis J, Sobczak-Th\u00e9pot J, Haddada H, Chiron M, Janicot M, Janot F, Tursz T, Vassal G (2000) p53-dependent G2 arrest associated with a decrease in cyclins A2 and B1 levels in a human carcinoma cell line. Br J Cancer 82(3):642\u2013650","journal-title":"Br J Cancer"},{"issue":"20","key":"4386_CR44","doi-asserted-by":"publisher","first-page":"5546","DOI":"10.1158\/1078-0432.CCR-12-0977","volume":"18","author":"DM Miller","year":"2012","unstructured":"Miller DM, Thomas SD, Ashraful I, David M, Kara S (2012) c-Myc and cancer metabolism. Clin Cancer Res 18(20):5546\u20135553","journal-title":"Clin Cancer Res"},{"issue":"11","key":"4386_CR45","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1038\/nrc1736","volume":"5","author":"SW Fesik","year":"2005","unstructured":"Fesik SW (2005) Promoting apoptosis as a strategy for cancer drug discovery. Nat Rev Cancer 5(11):876\u2013885","journal-title":"Nat Rev Cancer"},{"issue":"5324","key":"4386_CR46","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1126\/science.277.5324.370","volume":"277","author":"B Antonsson","year":"1997","unstructured":"Antonsson B, Conti F, Ciavatta A, Montessuit S, Lewis S, Martinou I, Bernasconi L, Bernard A, Mermod JJ, Mazzei G (1997) Inhibition of Bax channel-forming activity by Bcl-2. Science 277(5324):370\u2013372","journal-title":"Science"},{"issue":"6","key":"4386_CR47","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/j.freeradbiomed.2009.12.022","volume":"48","author":"ML Circu","year":"2010","unstructured":"Circu ML, Aw TY (2010) Reactive oxygen species, cellular redox systems, and apoptosis. Free Radic Biol Med 48(6):749\u2013762","journal-title":"Free Radic Biol Med"},{"issue":"9","key":"4386_CR48","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/nrd4596","volume":"14","author":"JL Adams","year":"2015","unstructured":"Adams JL, Smothers J, Srinivasan R, Hoos A (2015) Big opportunities for small molecules in immuno-oncology. Nat Rev Drug Discov 14(9):603\u2013622","journal-title":"Nat Rev Drug Discov"},{"issue":"12","key":"4386_CR49","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.2217\/imt.14.86","volume":"6","author":"M Wang","year":"2014","unstructured":"Wang M, Yin B, Wang HY, Wang RF (2014) Current advances in T-cell-based cancer immunotherapy. Immunotherapy 6(12):1265\u20131278. https:\/\/doi.org\/10.2217\/imt.14.86","journal-title":"Immunotherapy"},{"issue":"3","key":"4386_CR50","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/s41573-019-0052-1","volume":"19","author":"N Shimasaki","year":"2020","unstructured":"Shimasaki N, Jain A, Campana D (2020) NK cells for cancer immunotherapy. Nat Rev Drug Discov 19(3):200\u2013218. https:\/\/doi.org\/10.1038\/s41573-019-0052-1","journal-title":"Nat Rev Drug Discov"},{"issue":"12","key":"4386_CR51","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/j.it.2016.09.006","volume":"37","author":"A Gardner","year":"2016","unstructured":"Gardner A, Ruffell B (2016) Dendritic cells and cancer immunity. Trends Immunol 37(12):855\u2013865. https:\/\/doi.org\/10.1016\/j.it.2016.09.006","journal-title":"Trends Immunol"},{"key":"4386_CR52","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00188","author":"J Zhou","year":"2020","unstructured":"Zhou J, Tang Z, Gao S, Li C, Feng Y, Zhou X (2020) Tumor-associated macrophages: recent insights and therapies. Front Oncol. https:\/\/doi.org\/10.3389\/fonc.2020.00188","journal-title":"Front Oncol"},{"key":"4386_CR53","doi-asserted-by":"publisher","DOI":"10.3390\/cells9030561","author":"AMK Law","year":"2020","unstructured":"Law AMK, Valdes-Mora F, Gallego-Ortega D (2020) Myeloid-derived suppressor cells as a therapeutic target for cancer. Cells. https:\/\/doi.org\/10.3390\/cells9030561","journal-title":"Cells"},{"issue":"5","key":"4386_CR54","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1007\/s00109-019-01762-4","volume":"97","author":"JH Park","year":"2019","unstructured":"Park JH, Park HJ, Lee SE, Kim YS, Jang GY, Han HD, Jung ID, Shin KC, Bae YM, Kang TH, Park YM (2019) Repositioning of the antipsychotic drug TFP for sepsis treatment. J Mol Med (Berl) 97(5):647\u2013658. https:\/\/doi.org\/10.1007\/s00109-019-01762-4","journal-title":"J Mol Med (Berl)"},{"issue":"3","key":"4386_CR55","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.devcel.2019.04.012","volume":"49","author":"Y Gao","year":"2019","unstructured":"Gao Y, Bado I, Wang H, Zhang W, Rosen JM, Zhang XH-F (2019) Metastasis organotropism: redefining the congenial soil. Dev Cell 49(3):375\u2013391","journal-title":"Dev Cell"},{"issue":"10","key":"4386_CR56","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1136\/gut.2010.211557","volume":"59","author":"E Mitry","year":"2010","unstructured":"Mitry E, Guiu B, Cosconea S, Jooste V, Faivre J, Bouvier A-M (2010) Epidemiology, management and prognosis of colorectal cancer with lung metastases: a 30-year population-based study. Gut 59(10):1383\u20131388","journal-title":"Gut"},{"issue":"11","key":"4386_CR57","doi-asserted-by":"publisher","first-page":"2828","DOI":"10.1158\/1078-0432.ccr-13-0043","volume":"19","author":"MA Smith","year":"2013","unstructured":"Smith MA, Houghton P (2013) A proposal regarding reporting of in vitro testing results. Clin Cancer Res 19(11):2828\u20132833. https:\/\/doi.org\/10.1158\/1078-0432.ccr-13-0043","journal-title":"Clin Cancer Res"},{"issue":"6","key":"4386_CR58","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/bf00315316","volume":"45","author":"PK Yeung","year":"1993","unstructured":"Yeung PK, Hubbard JW, Korchinski ED, Midha KK (1993) Pharmacokinetics of chlorpromazine and key metabolites. Eur J Clin Pharmacol 45(6):563\u2013569. https:\/\/doi.org\/10.1007\/bf00315316","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"4386_CR59","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1002\/cpt.1211","volume":"106","author":"IH Bartelink","year":"2019","unstructured":"Bartelink IH, Jones EF, Shahidi-Latham SK, Lee PRE, Zheng Y, Vicini P, van\u2019t Veer L, Wolf D, Iagaru A, Kroetz DL, Prideaux B, Cilliers C, Thurber GM, Wimana Z, Gebhart G (2019) Tumor drug penetration measurements could be the neglected piece of the personalized cancer treatment puzzle. Clin Pharmacol Ther 106(1):148\u2013163. https:\/\/doi.org\/10.1002\/cpt.1211","journal-title":"Clin Pharmacol Ther"},{"issue":"22","key":"4386_CR60","doi-asserted-by":"publisher","first-page":"5780","DOI":"10.3390\/cancers13225780","volume":"13","author":"L Molenaar-Kuijsten","year":"2021","unstructured":"Molenaar-Kuijsten L, van Meekeren M, Verheijen RB, Bov\u00e9e JVMG, Fiocco M, Thijssen B, Rosing H, Huitema ADR, Miah AB, Gelderblom H, Haas RLM, Steeghs N (2021) Intra-tumoral pharmacokinetics of pazopanib in combination with radiotherapy in patients with non-metastatic soft-tissue sarcoma. Cancers 13(22):5780","journal-title":"Cancers"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-021-04386-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-021-04386-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-021-04386-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,24]],"date-time":"2023-01-24T07:26:26Z","timestamp":1674545186000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-021-04386-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,24]]},"references-count":60,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["4386"],"URL":"https:\/\/doi.org\/10.1007\/s00280-021-04386-z","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,24]]},"assertion":[{"value":"29 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"On behalf of all authors, the corresponding author states that there is no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures in this study were performed in accordance with relevant guidelines and regulations. Ethical approval for the use of animal models was obtained from the Animal Care and Use Committee of Sichuan University.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}